Washington, D.C. — December 2025
The United States government is weighing a historic reclassification of marijuana, a move that would ease restrictions on medical research and potentially reshape the nation’s drug policy. According to Global News, the proposal could shift cannabis from its current Schedule I status reserved for substances deemed to have no medical use into a category that acknowledges its therapeutic potential.
Key Points:
• Current classification: Marijuana is listed as a Schedule I drug, alongside heroin and LSD, making research extremely difficult.
• Proposed change: Reclassification to Schedule III would recognize medical uses and allow regulated research, similar to substances like ketamine.
• Medical implications: Scientists could more easily study cannabis for treatments ranging from chronic pain to epilepsy.
• Economic impact: The cannabis industry, already worth billions, could see expanded legitimacy and investment opportunities.
• Political context: The move reflects growing public support for legalization, though critics warn of health risks and regulatory challenges.
Analysis:
Reclassification would mark one of the most significant shifts in U.S. drug policy in decades, aligning federal law more closely with state-level legalization trends. While it stops short of full legalization, the change could accelerate medical breakthroughs and reduce stigma around cannabis research. Opponents argue that risks of misuse remain, highlighting the tension between science, public health, and politics.
Closing:
If approved, the reclassification would signal a turning point in America’s approach to cannabis, opening doors for medical innovation while reigniting debates over regulation and public safety.
(Source – Global News)
—Owned Sources
Leave a Reply